Trials / Terminated
TerminatedNCT03335280
68Ga-citrate PET/MR Imaging for Glioma
68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- Susan Chang · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-citrate PET/MR | Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes. |
Timeline
- Start date
- 2019-02-26
- Primary completion
- 2020-04-24
- Completion
- 2020-04-24
- First posted
- 2017-11-07
- Last updated
- 2020-05-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03335280. Inclusion in this directory is not an endorsement.